Louise Chen
Stock Analyst at Cantor Fitzgerald
(2.26)
# 2,625
Out of 4,734 analysts
284
Total ratings
37%
Success rate
-0.81%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics | Reiterates: Overweight | n/a | $0.91 | - | 5 | Nov 15, 2024 | |
| NVO Novo Nordisk | Reiterates: Overweight | $160 | $78.69 | +103.33% | 20 | Nov 6, 2024 | |
| PCVX Vaxcyte | Reiterates: Overweight | n/a | $85.30 | - | 6 | Nov 6, 2024 | |
| PFE Pfizer | Reiterates: Overweight | $45 | $26.30 | +71.10% | 30 | Oct 25, 2024 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $26.05 | - | 7 | Oct 25, 2024 | |
| JNJ Johnson & Johnson | Reiterates: Overweight | $215 | $147.03 | +46.23% | 40 | Oct 16, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | n/a | $8.05 | - | 5 | Oct 11, 2024 | |
| MRK Merck & Co. | Reiterates: Overweight | $155 | $97.92 | +58.29% | 25 | Oct 3, 2024 | |
| ROIV Roivant Sciences | Reiterates: Overweight | n/a | $11.15 | - | 9 | Sep 19, 2024 | |
| LLY Eli Lilly | Reiterates: Overweight | $885 | $725.72 | +21.95% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.51 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $23.86 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.30 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.19 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.70 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $171.56 | +16.58% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.58 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.83 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.01 | - | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.05 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.56 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.45 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $681.58 | +35.71% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.12 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $10.31 | +530.46% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.57 | - | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.05 | +376.19% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $1.07 | +2,236.45% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.20 | +252.11% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $12.68 | +294.32% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.06 | +371.70% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $2.70 | +233.33% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $21 | $0.48 | +4,302.52% | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $67,500 | $0.85 | +7,987,120.45% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $462.99 | -44.28% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $21.92 | -31.57% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.63 | +2,967.48% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.47 | +1,260.54% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $3.68 | +1,258.70% | 1 | Jul 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.66 | +1,129.51% | 1 | Jun 22, 2017 |
Spero Therapeutics
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.91
Upside: -
Novo Nordisk
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $78.69
Upside: +103.33%
Vaxcyte
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $85.30
Upside: -
Pfizer
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.30
Upside: +71.10%
Zai Lab
Oct 25, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.05
Upside: -
Johnson & Johnson
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $147.03
Upside: +46.23%
Zevra Therapeutics
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.05
Upside: -
Merck & Co.
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $97.92
Upside: +58.29%
Roivant Sciences
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.15
Upside: -
Eli Lilly
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $725.72
Upside: +21.95%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.51
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.86
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.30
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.19
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.70
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $171.56
Upside: +16.58%
Aug 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.58
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.83
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.01
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.05
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.56
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.45
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $681.58
Upside: +35.71%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.12
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $10.31
Upside: +530.46%
Nov 14, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.57
Upside: -
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.05
Upside: +376.19%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $1.07
Upside: +2,236.45%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.20
Upside: +252.11%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $12.68
Upside: +294.32%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.06
Upside: +371.70%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $2.70
Upside: +233.33%
May 10, 2023
Maintains: Neutral
Price Target: $33 → $21
Current: $0.48
Upside: +4,302.52%
Jul 7, 2021
Initiates: Overweight
Price Target: $67,500
Current: $0.85
Upside: +7,987,120.45%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $462.99
Upside: -44.28%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $21.92
Upside: -31.57%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.63
Upside: +2,967.48%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.47
Upside: +1,260.54%
Jul 21, 2017
Initiates: Overweight
Price Target: $50
Current: $3.68
Upside: +1,258.70%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $3.66
Upside: +1,129.51%